![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan (R.F., M.N., H.Y., A.N., M.K., T.Y.); and Food Science and Technology, Biotechnology Research Center, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan (S.I., T.S.)
We established stable HEK293 cell lines expressing double isoforms, UGT1A1 and UGT1A9, UGT1A4 and UGT1A9, or UGT1A6 and UGT1A9, as well as stable cell lines expressing each single isoform. To analyze the protein-protein interaction between the UGT1As, we investigated the thermal stability and resistance to detergent. UGT1A9 uniquely demonstrated thermal stability, which was enhanced in the presence of UDP-glucuronic acid (>90% of control), and resistance to detergent. Interestingly, UGT1A1, UGT1A4, and UGT1A6 acquired thermal stability and resistance to detergent by the coexpression of UGT1A9. An immunoprecipitation assay revealed that UGT1A6 and UGT1A9 interact in the double expression system. Using the single expression systems, it was confirmed that estradiol 3-O-glucuronide, imipramine N-glucuronide, serotonin O-glucuronide, and propofol O-glucuronide formations are specific for UGT1A1, UGT1A4, UGT1A6, and UGT1A9, respectively. By kinetic analyses, we found that the coexpressed UGT1A9 significantly affected the kinetics of estradiol 3-O-glucuronide formation (decreased Vmax), imipramine N-glucuronide formation (increased Km and Vmax), and serotonin O-glucuronide formation (decreased Vmax) catalyzed by UGT1A1, UGT1A4, and UGT1A6, respectively. On the other hand, the coexpressed UGT1A1 increased Km and decreased the Vmax of the propofol O-glucuronide formation catalyzed by UGT1A9. The coexpressed UGT1A4 and UGT1A6 also increased the Vmax of the propofol Oglucuronide formation by UGT1A9. This is the first study showing that human UGT1A isoforms interact with other isoforms to change the enzymatic characteristics.
This article has been cited by other articles:
![]() |
R. Fujiwara, M. Nakajima, H. Yamanaka, and T. Yokoi Key Amino Acid Residues Responsible for the Differences in Substrate Specificity of Human UDP-Glucuronosyltransferase (UGT)1A9 and UGT1A8 Drug Metab. Dispos., January 1, 2009; 37(1): 41 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shiratani, M. Katoh, M. Nakajima, and T. Yokoi Species Differences in UDP-Glucuronosyltransferase Activities in Mice and Rats Drug Metab. Dispos., September 1, 2008; 36(9): 1745 - 1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates Drug Metab. Dispos., February 1, 2008; 36(2): 361 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Omura, T. Nakazawa, T. Sato, T. Iwanaga, and O. Nagata Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor Drug Metab. Dispos., December 1, 2007; 35(12): 2143 - 2148. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhang, D. Zhang, D. Cui, J. Gambardella, L. Ma, A. Barros, L. Wang, Y. Fu, S. Rahematpura, J. Nielsen, et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism Drug Metab. Dispos., December 1, 2007; 35(12): 2270 - 2280. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic Activities Drug Metab. Dispos., October 1, 2007; 35(10): 1781 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakajima, H. Yamanaka, R. Fujiwara, M. Katoh, and T. Yokoi Stereoselective Glucuronidation of 5-(4'-Hydroxyphenyl)-5-phenylhydantoin by Human UDP-Glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: Effects of UGT-UGT Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1679 - 1686. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamanaka, M. Nakajima, M. Katoh, and T. Yokoi Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes Drug Metab. Dispos., September 1, 2007; 35(9): 1642 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mano, T. Usui, and H. Kamimura Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Racemic Flurbiprofen in the Human Liver Drug Metab. Dispos., July 1, 2007; 35(7): 1182 - 1187. [Abstract] [Full Text] [PDF] |
||||